The effect of a novel C5 inhibitor (K-76 COONa) on tumor cell chemotaxis. 1983

H L Bumpers, and J Baum

Walker carcinosarcoma cells were cultured as an ascitic tumor in the rat. These cells were studied for their response to human chemotactic factors derived from complement. Complement activation for tumor chemotaxis was performed by reaction of serum with a tumor extract. An anticomplementary agent, K-76 sodium monocarboxylic acid (K-76 COONa), was tested in these systems. It was found to be effective in blocking the formation of a chemotactic factor for tumor cells from human complement at a concentration of 300 micrograms/ml. Addition of K-76 COONa after complement activation had no effect. No effect on random migration of tumor cells was found at concentrations of 500 micrograms/ml. No effect on tumor cell viability was found up to 500 micrograms/ml. At 1000 micrograms/ml there was a 15% decrease in viability (p less than 0.05). Since chemotactic mechanisms (probably from activated complement) may play a role in the movement of tumor cells, this apparently low toxic anticomplementary agent (K-76 COONa) may be of value in the prevention of tumor metastases.

UI MeSH Term Description Entries
D002279 Carcinoma 256, Walker A transplantable carcinoma of the rat that originally appeared spontaneously in the mammary gland of a pregnant albino rat, and which now resembles a carcinoma in young transplants and a sarcoma in older transplants. (Stedman, 25th ed) Carcinosarcoma 256, Walker,Walker Carcinoma 256,Walker Carcinosarcoma 256
D002633 Chemotaxis The movement of cells or organisms toward or away from a substance in response to its concentration gradient. Haptotaxis
D003169 Complement Inactivator Proteins Serum proteins that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host. The complement system is tightly regulated by inactivators that accelerate the decay of intermediates and certain cell surface receptors. Complement Cytolysis Inhibiting Proteins,Complement Cytolysis Inhibitor Proteins,Complement Inactivating Proteins,Serum Complement Inactivators,Complement Inactivators, Serum,Inactivating Proteins, Complement,Inactivator Proteins, Complement,Inactivators, Serum Complement,Proteins, Complement Inactivating,Proteins, Complement Inactivator
D003182 Complement C5 C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX. C5 Complement,Complement 5,Complement C5, Precursor,Complement Component 5,Precursor C5,Pro-C5,Pro-complement 5,C5, Complement,C5, Precursor,C5, Precursor Complement,Complement, C5,Component 5, Complement,Precursor Complement C5,Pro C5,Pro complement 5
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012717 Sesquiterpenes Fifteen-carbon compounds formed from three isoprenoid units with general formula C15H24. Farnesanes,Farnesene,Farnesenes,Sesquiterpene,Sesquiterpene Derivatives,Sesquiterpenoid,Sesquiterpenoids,Derivatives, Sesquiterpene
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

H L Bumpers, and J Baum
September 2006, The Journal of pharmacology and experimental therapeutics,
H L Bumpers, and J Baum
January 2019, Therapeutic advances in hematology,
H L Bumpers, and J Baum
February 1990, American journal of respiratory cell and molecular biology,
H L Bumpers, and J Baum
January 2001, Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica,
H L Bumpers, and J Baum
August 2008, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
H L Bumpers, and J Baum
November 2022, Oncology letters,
H L Bumpers, and J Baum
April 2012, Lung cancer (Amsterdam, Netherlands),
Copied contents to your clipboard!